DOCSLIB.ORG

Pharmaceuticals Appendix

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceuticals Appendix )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACTAGARDIN ABAFUNGIN 129639-79-8 ACTAPLANIN 37305-75-2 ABAMECTIN 65195-55-3 ACTARIT 18699-02-0 ABANOQUIL 90402-40-7 ACTINOQUINOL 15301-40-3 ABARELIX 183552-38-7 ACTISOMIDE 96914-39-5 ABCIXIMAB 143653-53-6 ACTODIGIN 36983-69-4 ABECARNIL 111841-85-1 ADAFENOXATE 82168-26-1 ABIRATERONE 154229-19-3 ADAMEXINE 54785-02-3 ABITESARTAN 137882-98-5 ADAPALENE 106685-40-9 ABLUKAST 96566-25-5 ADAPROLOL 101479-70-3 ABUNIDAZOLE 91017-58-2 ADATANSERIN 127266-56-2 ACADESINE 2627-69-2 ADEFOVIR 106941-25-7 ACAMPROSATE 77337-76-9 ADELMIDROL 1675-66-7 ACAPRAZINE 55485-20-6 ADEMETIONINE 17176-17-9 ACARBOSE 56180-94-0 ADENOSINE PHOSPHATE 61-19-8 ACEBROCHOL 514-50-1 ADIBENDAN 100510-33-6 ACEBURIC ACID 26976-72-7 ADICILLIN 525-94-0 ACEBUTOLOL 37517-30-9 ADIMOLOL 78459-19-5 ACECAINIDE 32795-44-1 ADINAZOLAM 37115-32-5 ACECARBROMAL 77-66-7 ADIPHENINE 64-95-9 ACECLIDINE 827-61-2 ADIPIODONE 606-17-7 ACECLOFENAC 89796-99-6 ADITEREN 56066-19-4 ACEDAPSONE 77-46-3 ADITOPRIM 56066-63-8 ACEDIASULFONE SODIUM 127-60-6 ADOSOPINE 88124-26-9 ACEDOBEN 556-08-1 ADOZELESIN 110314-48-2 ACEFLURANOL 80595-73-9 ADRAFINIL 63547-13-7 ACEFURTIAMINE 10072-48-7 ADRENALONE 99-45-6 ACEFYLLINE PIPERAZINE 18428-63-2 AFALANINE 2901-75-9 ACEFYLLINE CLOFIBROL 70788-27-1 AFELIMOMAB 156227-98-4 ACEGLATONE 642-83-1 AFLOQUALONE 56287-74-2 ACEGLUTAMIDE 2490-97-3 AFOVIRSEN 151356-08-0 ACEMANNAN 110042-95-0 AFUROLOL 65776-67-2 ACEMETACIN 53164-05-9 AGANODINE 86696-87-9 ACENEURAMIC ACID 131-48-6 AGLEPRISTONE 124478-60-0 ACENOCOUMAROL 152-72-7 AGOMELATINE 138112-76-2 ACEPERONE 807-31-8 AKLOMIDE 3011-89-0 ACEPROMAZINE 61-00-7 ALACEPRIL 74258-86-9 ACEPROMETAZINE 13461-01-3 ALAFOSFALIN 60668-24-8 ACEQUINOLINE 42465-20-3 ALANINE 56-41-7 ACESULFAME 33665-90-6 ALANOSINE 5854-93-3 ACETAMINOSALOL 118-57-0 ALAPROCLATE 60719-82-6 ACETARSOL 97-44-9 ALATROFLOXACIN 157182-32-6 ACETAZOLAMIDE 59-66-5 ALAZANINE TRICLOFENATE 5779-59-9 ACETERGAMINE 3031-48-9 ALBENDAZOLE 54965-21-8 ACETIAMINE 299-89-8 ALBENDAZOLE OXIDE 54029-12-8 ACETIROMATE 2260-08-4 ALBIFYLLINE 107767-55-5 ACETOHEXAMIDE 968-81-0 ALBUTOIN 830-89-7 ACETOHYDROXAMIC ACID 546-88-3 ALCLOFENAC 22131-79-9 ACETOPHENAZINE 2751-68-0 ALCLOMETASONE 67452-97-5 ACETORPHINE 25333-77-1 ALCLOXA 1317-25-5 ACETRYPTINE 3551-18-6 ALCURONIUM CHLORIDE 15180-03-7 ACETYLCHOLINE CHLORIDE 60-31-1 ALDESULFONE SODIUM 144-75-2 ACETYLCYSTEINE 616-91-1 ALDIOXA 5579-81-7 ACETYLDIGITOXIN 1111-39-3 ALDOSTERONE 52-39-1 ACETYLLEUCINE 99-15-0 ALENDRONIC ACID 66376-36-1 ACETYLMETHADOL 509-74-0 ALENTEMOL 112891-97-1 ACEVALTRATE 25161-41-5 ALEPRIDE 66564-15-6 ACEXAMIC ACID 57-08-9 ALESTRAMUSTINE 139402-18-9 ACICLOVIR 59277-89-3 ALEXIDINE 22573-93-9 ACIFRAN 72420-38-3 ALEXITOL SODIUM 66813-51-2 ACIPIMOX 51037-30-0 ALFACALCIDOL 41294-56-8 ACITAZANOLAST 114607-46-4 ALFADEX 10016-20-3 ACITEMATE 101197-99-3 ALFADOLONE 14107-37-0 ACITRETIN 55079-83-9 ALFAPROSTOL 74176-31-1 ACIVICIN 42228-92-2 ALFAXALONE 23930-19-0 ACLANTATE 39633-62-0 ALFENTANIL 71195-58-9 ACLARUBICIN 57576-44-0 ALFETAMINE 4255-23-6 ACLATONIUM NAPADISILATE 55077-30-0 ALFUZOSIN 81403-80-7 ACODAZOLE 79152-85-5 ALGELDRATE 1330-44-5 ACONIAZIDE 13410-86-1 ALGESTONE 595-77-7 ACOXATRINE 748-44-7 ALGLUCERASE 143003-46-7 ACREOZAST 123548-56-1 ALIBENDOL 26750-81-2 ACRIDOREX 47487-22-9 ALICONAZOLE 63824-12-4 ACRIFLAVINIUM CHLORIDE 8063-24-9 ALIFEDRINE 78756-61-3 ACRIHELLIN 67696-82-6 ALIFLURANE 56689-41-9 ACRISORCIN 7527-91-5 ALIMADOL 52742-40-2 ACRIVASTINE 87848-99-5 ALIMEMAZINE 84-96-8 ACROCINONIDE 28971-58-6 ALINASTINE 154541-72-7 ACRONINE 7008-42-6 ALINIDINE 33178-86-8 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 Table 1 (con.) Product CAS Number Product CAS Number ALIPAMIDE 3184-59-6 AMEZEPINE 60575-32-8 ALIZAPRIDE 59338-93-1 AMEZINIUM METILSULFATE 30578-37-1 ALLETORPHINE 23758-80-7 AMFEBUTAMONE 34911-55-2 ALLOBARBITAL 52-43-7 AMFECLORAL 5581-35-1 ALLOCLAMIDE 5486-77-1 AMFENAC 51579-82-9 ALLOCUPREIDE SODIUM 5965-40-2 AMFEPENTOREX 15686-27-8 ALLOMETHADIONE 526-35-2 AMFEPRAMONE 90-84-6 ALLOPURINOL 315-30-0 AMFETAMINE 300-62-9 ALLYLESTRENOL 432-60-0 AMFETAMINIL 17590-01-1 ALLYLPRODINE 25384-17-2 AMFLUTIZOLE 82114-19-0 ALLYLTHIOUREA 109-57-9 AMFOMYCIN 1402-82-0 ALMADRATE SULFATE 60239-66-9 AMFONELIC ACID 15180-02-6 ALMAGATE 66827-12-1 AMICARBALIDE 3459-96-9 ALMAGODRATE AMICIBONE 23271-63-8 ALMASILATE 71205-22-6 AMICYCLINE 5874-95-3 ALMECILLIN 87-09-2 AMIDANTEL 49745-00-8 ALMESTRONE 10448-96-1 AMIDAPSONE 3569-77-5 ALMINOPROFEN 39718-89-3 AMIDEFRINE MESILATE 1421-68-7 ALMITRINE 27469-53-0 AMIFLAMINE 77518-07-1 ALMOKALANT 123955-10-2 AMIFLOVERINE 54063-24-0 ALMOTRIPTAN 154323-57-6 AMIFLOXACIN 86393-37-5 ALMOXATONE 84145-89-1 AMIFOSTINE 20537-88-6 ALMURTIDE 61136-12-7 AMIKACIN 37517-28-5 ALNESPIRONE 138298-79-0 AMIKHELLINE 4439-67-2 ALNIDITAN 152317-89-0 AMILORIDE 2609-46-3 ALONACIC 105292-70-4 AMINDOCATE 31386-24-0 ALONIMID 2897-83-8 AMINEPTINE 57574-09-1 ALORACETAM 119610-26-3 AMINITROZOLE 140-40-9 ALOSETRON 122852-42-0 AMINOACRIDINE 90-45-9 ALOVUDINE 25526-93-6 AMINOCAPROIC ACID 60-32-2 ALOXIPRIN 9014-67-9 AMINOETHYL NITRATE 646-02-6 ALOXISTATIN 88321-09-9 AMINOGLUTETHIMIDE 125-84-8 ALOZAFONE 65899-72-1 AMINOMETRADINE 642-44-4 ALPERTINE 27076-46-6 AMINOPHENAZONE 58-15-1 ALPHACETYLMETHADOL 17199-58-5 AMINOPHENAZONE CYCLAMATE 747-30-8 ALPHAMEPRODINE 468-51-9 AMINOPHYLLINE 317-34-0 ALPHAMETHADOL 17199-54-1 AMINOPROMAZINE 58-37-7 ALPHAPRODINE 77-20-3 AMINOPTERIN SODIUM 58602-66-7 ALPIDEM 82626-01-5 AMINOQUINOL 10023-54-8 ALPIROPRIDE 81982-32-3 AMINOQUINURIDE 3811-56-1 ALPRAFENONE 124316-02-5 AMINOREX 2207-50-3 ALPRAZOLAM 28981-97-7 AMINOTHIAZOLE 96-50-4 ALPRENOLOL 13655-52-2 AMINOXYTRIPHENE 5585-64-8 ALPROSTADIL 745-65-3 AMIODARONE 1951-25-3 ALRESTATIN 51411-04-2 AMIPERONE 1580-71-8 ALSACTIDE 34765-96-3 AMIPHENAZOLE 490-55-1 ALTANSERIN 76330-71-7 AMIPIZONE 69635-63-8 ALTAPIZONE 93277-96-4 AMIPRILOSE 56824-20-5 ALTECONAZOLE 93479-96-0 AMIQUINSIN 13425-92-8 ALTEPLASE 105857-23-6 AMISOMETRADINE 550-28-7 ALTIZIDE 5588-16-9 AMISULPRIDE 71675-85-9 ALTOQUALINE 121029-11-6 AMITEROL 54063-25-1 ALTRENOGEST 850-52-2 AMITIVIR 111393-84-1 ALTRETAMINE 645-05-6 AMITRAZ 33089-61-1 ALTUMOMAB 156586-92-4 AMITRIPTYLINE 50-48-6 ALUMINIUM CLOFIBRATE 24818-79-9 AMITRIPTYLINOXIDE 4317-14-0 ALUSULF 61115-28-4 AMIXETRINE 24622-72-8 ALVERINE 150-59-4 AMLEXANOX 68302-57-8 ALVIRCEPT SUDOTOX 137487-62-8 AMLINTIDE 122384-88-7 AMADINONE 30781-27-2 AMLODIPINE 88150-42-9 AMAFOLONE 50588-47-1 AMOBARBITAL 57-43-2 AMANOZINE 537-17-7 AMOCARZINE 36590-19-9 AMANTADINE 768-94-5 AMODIAQUINE 86-42-0 AMANTANIUM BROMIDE 58158-77-3 AMOGASTRIN 16870-37-4 AMANTOCILLIN 10004-67-8 AMOLANONE 76-65-3 AMBAMUSTINE 85754-59-2 AMONAFIDE 69408-81-7 AMBASILIDE 83991-25-7 AMOPROXAN 22661-76-3 AMBAZONE 539-21-9 AMOPYROQUINE 550-81-2 AMBENONIUM CHLORIDE 115-79-7 AMOROLFINE 78613-35-1 AMBENOXAN 2455-84-7 AMOSCANATE 26328-53-0 AMBICROMIL 58805-38-2 AMOSULALOL 85320-68-9 AMBOMYCIN 1402-81-9 AMOXAPINE 14028-44-5 AMBROXOL 18683-91-5 AMOXECAINE 553-65-1 AMBRUTICIN 58857-02-6 AMOXICILLIN 26787-78-0 AMBUCAINE 119-29-9 AMOXYDRAMINE CAMSILATE 15350-99-9 AMBUCETAMIDE 519-88-0 AMPEROZIDE 75558-90-6 AMBUSIDE 3754-19-6 AMPHENIDONE 134-37-2 AMCINAFAL 3924-70-7 AMPHOTALIDE 1673-06-9 AMCINAFIDE 7332-27-6 AMPHOTERICIN B 1397-89-3 AMCINONIDE 51022-69-6 AMPICILLIN 69-53-4 AMEBUCORT 83625-35-8 AMPIROXICAM 99464-64-9 AMEDALIN 22136-26-1 AMPROLIUM 121-25-5 AMELOMETASONE 123013-22-9 AMPYRIMINE 5587-93-9 AMELTOLIDE 787-93-9 AMPYZINE 5214-29-9 AMESERGIDE 121588-75-8 AMQUINATE 17230-85-2 AMETANTRONE 64862-96-0 AMRINONE 60719-84-8 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 5 Table 1 (con.) ProductCAS Number Product CAS Number AMRUBICIN 110267-81-7 ARTEFLENE 123407-36-3 AMSACRINE 51264-14-3 ARTEMETHER 71963-77-4 AMTOLMETIN GUACIL 87344-06-7 ARTEMISININ 63968-64-9 AMYLMETACRESOL 1300-94-3 ARTESUNATE 88495-63-0 ANAGESTONE 2740-52-5 ARTICAINE 23964-58-1 ANAGRELIDE 68475-42-3 ARTILIDE 133267-19-3 ANAKINRA 143090-92-0 ASCORBIC ACID 50-81-7 ANARITIDE 95896-08-5 ASERIPIDE 153242-02-5 ANASTROZOLE 120511-73-1 ASIMADOLINE 153205-46-0 ANAXIRONE 77658-97-0 ASOBAMAST 104777-03-9 ANAZOCINE 15378-99-1 ASOCAINOL 77400-65-8 ANAZOLENE SODIUM 3861-73-2 ASPARTAME 22839-47-0 ANCAROLOL 75748-50-4 ASPARTIC ACID 56-84-8 ANCITABINE 31698-14-3 ASPARTOCIN 4117-65-1 ANCROD 9046-56-4 ASPOXICILLIN 63358-49-6 ANDOLAST 132640-22-3 ASTEMIZOLE 68844-77-9 ANDROSTANOLONE 521-18-6 ASTROMICIN 55779-06-1 ANGIOTENSIN II 4474-91-3 ATAMESTANE 96301-34-7 ANGIOTENSINAMIDE 53-73-6 ATAPROST 83997-19-7 ANIDOXIME 34297-34-2 ATENOLOL 29122-68-7 ANILAMATE 5591-49-1 ATEVIRDINE 136816-75-6 ANILERIDINE 144-14-9 ATEXAKIN ALFA 143631-61-2 ANILOPAM 53716-46-4 ATIBEPRONE 153420-96-3 ANIPAMIL 83200-10-6 ATIPAMEZOLE 104054-27-5 ANIRACETAM 72432-10-1 ATIPRIMOD 123018-47-3 ANIROLAC 66635-85-6 ATIPROSIN 89303-63-9 ANISACRIL 5129-14-6 ATIZORAM 135637-46-6 ANISINDIONE 117-37-3 ATLIPROFEN 108912-17-0 ANISOPIROL 442-03-5 ATOLIDE 16231-75-7 ANISTREPLASE 81669-57-0 ATORVASTATIN 134523-00-5 ANITRAZAFEN 63119-27-7 ATOSIBAN 90779-69-4
Load more

Recommended publications
  • Meprobamate Art 107 AR
    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
    [Show full text]
  • Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models
    Technische Universität München Automated annotation of structurally uncharacterized metabolites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell 2019 Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Technische Universität München Lehrstuhl für Experimentelle Bioinformatik Automated annotation of structurally uncharacterized metabo- lites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Er- nährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Prof. Dr. Dmitrij Frischmann Prüfer der Dissertation: 1. Prof. Dr. Hans-Werner Mewes 2. Prof. Dr. Bernhard Küster Die Dissertation wurde am 28.11.2018 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 28.01.2019 angenommen. „Der Mensch muß bei dem Glauben verharren, daß das Unbegreifliche begreiflich sei; er würde sonst nicht forschen.“ Johann Wolfgang von Goethe i Danksagung Zunächst möchte ich mich ganz besonders bei meinem Doktorvater (Hans-)Werner Mewes bedanken, der mir nicht nur die Möglichkeit gegeben hat an seinem Institut des Helmholtz Zentrums München sowie seinem Lehrstuhl an der Technischen Uni- versität München in Forschung und Lehre zu arbeiten, sondern auch meine Laufbahn
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick
    bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Effects of N-Acetyl-Leucine and its enantiomers in Niemann-Pick disease type C cells Danielle te Vruchte1, Anthony Galione2, Michael Strupp3 and Michiko Mann1 1IntraBio Ltd, Oxford University Begbroke Science Park, Woodstock Road, Oxford, UK 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK 3Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany Corresponding author Danielle te Vruchte Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Conflicts of Interest A.G. is a cofounder, shareholder and consultant to IntraBio. M.Y-M and D.t.V. are shareholders in IntraBio. M.S. acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion, is a shareholder of IntraBio and Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. M.S. has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grunenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities
    77 A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities Hernán Pessoa-Mahana* 1 ; Ramiro Araya-Maturana1 , Claudio Saitz, B.1 and C. David Pessoa-Mahana2 1Departamento de Química Orgánica y Fisicoquímica. Facultad de Ciencias Químicas y Farmacéuticas. Universidad de Chile. Olivos 1007.Casilla 233. Santiago 1. Chile 2Departamento de Farmacia. Facultad de Química. Pontificia Universidad Católica de Chile. Vicuña Mackenna 4860-Casilla 306, Correo 22 Santiago-Chile Abstract: The present review discusses the synthetic strategies of new ligands exhibiting mainly 5-HT1A binding affinities. Specifically we focused our attention in the synthesis of compounds structurally related to arylpiperazine, 2-aminotetralin, and benzopyran derivatives. Keywords: serotonin, 5-HT1A ligands, arylpiperazines, aminotetralins, benzopyrans. INTRODUCTION During the last 15 years, seven distinct families of 5-HT receptors have been identified (5-HT1–5-HT7), and at least Depression is one of the most common illnesses, 15 subpopulations have been described for several of these affecting up to one-third of all people at the same time. [4,5]. The 5-HT1A receptors represent a major target for Depressive disorders encompass a variety of conditions neurobiological research and drug developments. A study on including two major forms of unipolar depression (i.e. major distribution of 5-HT1A receptors in the brains of various depression and dysthymia), adjustment disorders, animal species indicates that the highest densities are located subsyndromal depression (minor depression), seasonal in the hippocampus, septum, amygdale, and cortical limbic affective disorder (SAD), premenstrual dysphoric disorder areas. The 5-HT1A receptors located in the raphe nuclei are (PMDD), postpartum depression, atypical depression and known as somatodendritic autoreceptors.
    [Show full text]